Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Nephrology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: HEALTHCAPS INDIA LTD.

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Financing June 02, 2021

            Details:

            Based on research from Håvard Attramadal's lab at Oslo University Hospital, Tribune is developing a novel drug with a pan-antifibrotic mechanism of action targeting several fibrotic indications including diseases affecting the kidney, lung and liver.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NPH-022

            Therapeutic Area: Nephrology Product Name: NPH-022

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Xontogeny, LLC

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Financing May 12, 2021

            Details:

            Funds from the financing to be used to advance Nephraegis' lead compound through critical preclinical work. NPH-022 has demonstrated an impressive efficacy and safety profile in rodent models of renal injury, supporting its potential as a breakthrough candidate.

            Telara Pharma

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cilastatin

            Therapeutic Area: Nephrology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Arch Biopartners

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement April 15, 2021

            Details:

            Arch secures the commercial rights to the patents around the use of cilastatin that it does not already own. The patents held by Arch and Telara are now unified into one clinical development program to be led by Arch.